Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

19.66USD
2:18pm EST
Change (% chg)

$0.06 (+0.31%)
Prev Close
$19.60
Open
$19.60
Day's High
$19.80
Day's Low
$19.41
Volume
26,862
Avg. Vol
44,403
52-wk High
$28.56
52-wk Low
$12.04

Chart for

About

G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.... (more)

Overall

Beta: --
Market Cap(Mil.): $555.57
Shares Outstanding(Mil.): 28.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Medimmune Ventures Sells 133,906 Shares Of G1 Therapeutics Inc's Common Stock On Dec 1

* MEDIMMUNE VENTURES INC REPORTS SALE OF 133,906 SHARES OF G1 THERAPEUTICS INC'S COMMON STOCK ON DEC 1 AT $19.75 PER SHARE - SEC FILING Source text: (http://bit.ly/2iVgOvs) Further company coverage:

Dec 05 2017

BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer

* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER

Nov 28 2017

BRIEF-G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​

* G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​

Nov 08 2017

BRIEF-G1 Therapeutics qtrly ‍loss per share $0.55

* G1 therapeutics reports third quarter 2017 financial results and recent operational highlights

Nov 08 2017

BRIEF-G1 Therapeutics Q2 loss per share $1.09‍​

* G1 Therapeutics reports second quarter 2017 financial results and recent operational highlights

Aug 09 2017

Earnings vs. Estimates